Nymox Pharmaceutical Corporation is a leading research and development company specializing in therapeutics and diagnostics. With a focus on addressing the unmet needs of the aging male population in developed economies, Nymox develops innovative products to improve quality of life. Their flagship product is Fexapotide Triflutate (FT), a drug candidate targeting benign prostatic hyperplasia (BPH).

After completing Phase 3 development in over 70 clinical centers and involving more than 1700 patients, Nymox is preparing to seek approval in major economies worldwide. This breakthrough treatment offers long-term symptom relief in BPH without the side-effects associated with oral medications, providing patients with a single, pain-free treatment option in the doctor's office. Nymox is also focused on developing Fexapotide for early-stage, non-aggressive prostate cancer (PCA), addressing an unmet clinical need in elderly men.

Phase II trials have demonstrated significant long-term clinical benefits, including the delayed progression of the disease. Additionally, Nymox offers two innovative diagnostic products: NicAlert® and TobacAlert®. These tests accurately measure tobacco product exposure, providing valuable information for individuals and healthcare professionals.

Headquartered in Nassau, Bahamas, Nymox has offices in Canada, the United States, and Switzerland. The company is in the process of relocating its headquarters to Switzerland. With their dedication to research and development, Nymox continues to revolutionize healthcare for the aging male population, offering innovative solutions and improving quality of life